Apogenix
Heidelberg
About Apogenix
Apogenix is a clinical stage biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory diseases. The compound´s mechanism of action is either based on the targeted modulation of the programmed cell death (a.k.a. apoptosis - ß╝ü╧Ç╧î╧Ç╧ä╧ë╧â╬╣╧â is used in Greek to describe the "falling off" of leaves from trees) or on the inhibition of tumour cell growth. The lead product candidate of the company, APG101, is currently in a controlled phase II proof of concept study with GBM patients (GBM: Glioblastoma multiforme).
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $56.3M
- Funding stage: Late Stage Venture
- Last round: Grant (Feb 2016)
- Website: apogenix.com
- Phone: +49 6221 58608-0
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/apogenix-154041 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.